Eli Lilly has stopped showing competitors its opening moves.
As recently as February, the pharma giant publicly listed a substantial roster of drugs in phase 1 development. Lilly’s select-pipeline snapshot from Q4 2025 included early-stage cancer drugs, gene therapies, a PCSK9 gene editor and 16 additional new molecular entities whose targets were undisclosed. By its Q1 2026 update, however, the public pipeline began at phase 2.
The company’s current clinical development pipeline, dated Aug. 5, now states plainly: “Phase 1 projects are no longer disclosed.”
The shift closes a useful window into one of pharma’s most closely watched R&D engines. Lilly has not publicly explained the broader change, although its pipeline site says some molecules are not identified for competitive reasons.
Eli Lilly did not respond to a request for comment. But for pharma strategist Mike Rea, CEO of Then, If..., a new venture focused on decision-making in drug development, the competitive logic is straightforward — and, in his telling, blunt.
“If you’re thinking stuff in phase 1, why the fuck would you show anyone if you don’t have to?” he told PharmaVoice. “It’s like … if you can make your first 10 chess moves without showing your opponent. That’s where I think Lilly [is] at now.”
The significance of the change goes beyond preventing rivals from seeing a list of experimental drugs, Rea argued. It could also change how Lilly manages those drugs internally.
The cost of showing your hand
Phase 1 is typically where companies first test a drug in humans and begin learning about safety, pharmacology and dosing. Rea sees that period as something strategically broader: a chance to generate options, test assumptions and decide what deserves a larger commitment.
Publicly identifying an asset can make the last of those choices harder, he argued.
“People don’t like killing programs that have not failed,” he said.
Once a program is visible to investors, analysts and competitors, Rea said, a company can face a stronger pull to keep it alive even after the strategic case weakens. The drug may still work. It may simply no longer be the best use of capital. Or another indication, asset or market opportunity may become more attractive.
In Rea’s view, keeping more of that experimentation out of the corporate pipeline could lower the external baggage attached to those decisions.
For Lilly, it could mean testing more paths while absorbing the cost of learning what does not work and only making a public commitment when it has a clearer idea of what it wants the program to become.
“Then you’ve got a much more lean and purposeful phase 2 coming out of that,” Rea said.
This approach turns nondisclosure from a communications choice into a portfolio-management hypothesis: Phase 1 becomes less like the bottom rung of a public pipeline and more like internal decision space.
What disappears — and what doesn’t
Lilly’s early human studies will not become completely invisible. Individual programs can still surface through trial registries, scientific meetings, publications, regulatory disclosures, partnerships and other public channels.
Lilly’s April earnings materials also included supplemental slides listing selected early-phase neuroscience and oncology trials sourced to ClinicalTrials.gov, even as its formal select pipeline began at phase 2.
"If you haven’t told someone where you’re going, then you really don’t need to tell them what you’ve got."
Mike Rea
Pharma strategist, CEO of Then, If…
What Lilly has removed is different: a company-curated map showing outsiders which phase 1 assets it considers part of its active development portfolio at a particular moment.
That distinction matters because an early program can reveal more than its code name. An indication can signal which patient population Lilly values. A trial design can reveal dosing, formulation, combination or segmentation choices. In a crowded market, those details can tell rivals where Lilly sees white space before efficacy data arrive.
“If you haven’t told someone where you’re going, then you really don’t need to tell them what you’ve got,” as Rea put it.
Obesity is an intuitive example, Rea said. A maintenance study, a new dosing interval or a particular combination can give competitors clues about how Lilly intends to carve up a market where it is already stretching its GLP-1 franchise across drugs, combinations and indications.
“So suddenly you’ve got this interesting white space maneuver that no one’s seen until you’re deciding to go for it,” he said.
Competitors can still reconstruct pieces of Lilly’s early work. But without Lilly’s own phase 1 map, they have to do more of the reconstruction themselves — and may have less time to infer which experiments Lilly considers strategically important.
The potential advantage isn’t invisibility. It is time.
A luxury of scale
The strategy may apply particularly well to Lilly because its earliest pipeline does not have to perform the same fundraising and signaling job it does for a small biotech.
A young drugmaker may need to publicize a phase 1 program to raise capital, attract partners or justify its valuation. Lilly can fund a much larger set of experiments without asking each one to serve as an external financing signal.
Rea described Lilly less as one giant pipeline than as a collection of biotechs operating with the capital and infrastructure of a large pharma. That gives the company another option if an internal program does not produce what it needs: buy or license something else.
In that formulation, nondisclosure and dealmaking reinforce the same flexibility. Lilly can keep studying competitors and potential partners while revealing less about where its own earliest portfolio is crowded, thin or changing.
The phase 2 test
Time will tell if nondisclosure produces better R&D. Keeping phase 1 off the corporate pipeline could conceal indecision as easily as productive experimentation. And rivals that invest enough effort may still reconstruct significant parts of Lilly’s early portfolio from public evidence elsewhere.
The real test will come when Lilly’s surviving programs emerge. If the company uses the less-visible phase 1 period to kill more aggressively, explore more options and pursue less obvious opportunities, those decisions should eventually show up in phase 2 — through the mechanisms Lilly advances, the indications it chooses and the clinical strategies it brings forward.
That is where Lilly’s missing phase 1 column becomes more than a disclosure story. The consequential question is not whether outsiders can identify every molecule Lilly puts into the clinic. It is whether revealing less of the early portfolio gives Lilly room to make different decisions before anyone knows which decisions it has to make.
If the resulting phase 2 portfolio eventually looks meaningfully different, the strategic value may prove to be less about hiding drugs than preserving decision space.
“The risk would be if Lilly comes out and says, [our] phase 2 pipeline looks the same as everyone else’s. [Then] something hasn’t worked,” Rea said.
